PRME 8-K 2026-11-10

Prime Medicine, Inc. (PRME) 8-K dated 2026-11-10 — accession 0001628280-26-072713.

Prime Medicine, Inc. (PRME) is a biotechnology company listed on NASDAQ.

Prime Medicine, Inc. filed a 8-K on 2026-11-10. Accession 0001628280-26-072713.

This 8-K covers: Results of operations (Item 2.02), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.

Not investment advice. The PRME SEC hub lists recent forms. The stock page is the research view.